Recursion to Participate in Upcoming Investor Conferences
May 01, 2024 08:01 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
April 30, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Altitude Lab and the Small Business Administration (SBA) are pleased to announce Horizon, a commercialization program to connect startups to...
Recursion to Participate in Upcoming Investor Conference
April 02, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Publishes Annual Environmental, Social and Governance Report
March 26, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 26, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced...
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
March 01, 2024 14:58 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare...
Recursion to Participate in Upcoming Investor Conferences
March 01, 2024 07:59 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 27, 2024 16:05 ET
|
Recursion Pharmaceuticals
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the...
Recursion to Host Public L(earnings) Call on February 27
February 20, 2024 07:59 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Altitude Lab Startups Raise Over $120M in Capital
January 24, 2024 09:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altitude Lab today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020. Altitude Lab...
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
January 08, 2024 10:59 ET
|
Recursion Pharmaceuticals
SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a demonstration...